Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer



Status:Terminated
Conditions:Colorectal Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/1/2017
Start Date:April 2011
End Date:February 2017

Use our guide to learn which trials are right for you!

A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Study BT-CL-PGG-CRC1031 is a Phase 3, open-label, randomized, multi-center study. Qualified
subjects, who have KRAS wild type (WT) colorectal cancer will be randomized in a 2:1 ratio
to treatment with either Imprime PGG and cetuximab or cetuximab alone. Subjects will be
dosed until progression or discontinuation for some other reason. Efficacy will be assessed
via Response Evaluation Criteria in Early Tumors 1.1 (RECIST 1.1); computed tomography (CT)
scans will be conducted every 6 weeks. Safety, pharmacokinetics (PK), quality of life, and
biomarker parameters will also be assessed.

Study BT-CL-PGG-CRC1031 is a Phase 3, open-label, randomized, multi-center study. Qualified
subjects, who have KRAS WT colorectal cancer will be randomized in a 2:1 ratio to either:

Arm 1: Imprime PGG and cetuximab or Arm 2: Cetuximab

Approximately 795 subjects will be randomized into the study. Dosing will occur in 6-week
cycles. Imprime PGG will be dosed at 4 mg/kg and will be administered weekly in each cycle
(Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab (Arm 1
only). The initial cetuximab dose (both arms) will be 400 mg/m2 on Cycle 1/Day 1 and
subsequent doses will be 250 mg/m2 administered weekly in each cycle (Weeks 1-6/Days 1, 8,
15, 22, 29, and 36).

Subjects will be dosed until progressive disease (PD) per RECIST 1.1 or discontinuation of
study drug for other reasons; e.g., safety. Following completion of the treatment period of
the study, subjects will be monitored for survival until death or loss to follow-up. Tumor
measurements and determination of tumor responses will be evaluated according to RECIST 1.1.
Safety, PK, quality of life, and biomarker parameters will also be assessed.

Inclusion Criteria:

1. Is >18 years old;

2. Has recurrent or metastatic carcinoma of the colon or rectum with documented
histological or cytological confirmation;

3. Must be KRAS WT;

4. Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a
target lesion according to RECIST 1.1;

5. Has never received cetuximab or panitumumab, and has not received any treatment for
colorectal cancer within 30 days prior to the first dose of study treatment under
this protocol;

6. Has an Eastern Cooperative Oncology Group (ECOG) score of 0-1, with a life expectancy
of >3 months;

7. Has received at least 2 prior chemotherapeutic regimens for colorectal cancer;

8. Has adequate bone marrow reserve as evidenced by:

- Absolute neutrophil count ≥1,500/μL

- Platelets ≥100,000/μL;

9. Has adequate renal function as evidenced by serum creatinine ≤2.5 × the upper limit
of normal (ULN) for the reference lab;

10. Has adequate hepatic function as evidenced by:

- Aspartate aminotransferase ≤3 × ULN for the reference lab (≤5 × ULN for subjects
with known hepatic metastases)

- Alanine aminotransferase ≤3 × ULN for the reference lab (≤5 × ULN for subjects
with known hepatic metastases)

- Bilirubin <1.5 mg/dL or direct bilirubin <1.0 mg/dL

- Serum Albumin >3.0 gm/dL

11. Has read, understood and signed the informed consent form (ICF) approved by the
Independent Review Board/Independent Ethics Committee (IRB/IEC); and

12. If the subject is a woman of childbearing potential or a fertile man, he/she must
agree to use an effective form of contraception during the study and for 60 days
following the last dose of study drug (an effective form of contraception is
abstinence, a hormonal contraceptive, or a double-barrier method).

Exclusion Criteria:

1. Has a known hypersensitivity to cetuximab, murine proteins, or any component of
cetuximab;

2. Has a known hypersensitivity to baker's yeast or has an active yeast infection;

3. Has had previous exposure to Betafectin® or Imprime PGG;

4. Has an active, uncontrolled infection;

5. Has known untreated or symptomatic brain metastases;

6. Had a second malignancy within the previous 5 years, except for basal cell carcinoma,
cervical intra-epithelial neoplasia or treated prostate cancer with a
prostate-specific antigen (PSA) of <2.0 ng/mL;

7. Has known human immunodeficiency virus or acquired immune deficiency syndrome,
hepatitis B, hepatitis C, connective tissue disease, or other clinical diagnosis,
ongoing or intercurrent illness that in the Investigators opinion should preclude the
subject from participation;

8. If female, is pregnant or breast-feeding;

9. Is receiving concurrent standard and/or investigational anti-cancer therapy or has
received such therapy within a period of 30 days prior to the first scheduled day of
dosing (investigational therapy is defined as treatment for which there is currently
no regulatory-authority-approved indication); or

10. Has previously received an organ or progenitor/stem cell transplant.
We found this trial at
45
sites
Ogden, Utah 84403
?
mi
from
Ogden, UT
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
115 Business loop 70 w
Columbia, Missouri 65203
(573) 882-2100
Ellis Fischel Cancer Center at University of Missouri - Columbia At Ellis Fischel Cancer Center,...
?
mi
from
Columbia, MO
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
(612) 625-5000
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Amarillo, Texas 79106
?
mi
from
Amarillo, TX
Click here to add this to my saved trials
Anaheim, California 92801
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Bakersfield, California 93309
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Beech Grove, Indiana 46237
?
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Bentonville, Arkansas 72703
?
mi
from
Bentonville, AR
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Burbank, California 91505
?
mi
from
Burbank, CA
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denton, Texas 76210
?
mi
from
Denton, TX
Click here to add this to my saved trials
Detroit, Michigan 48202
?
mi
from
Detroit, MI
Click here to add this to my saved trials
East Syracuse, New York 13057
?
mi
from
East Syracuse, NY
Click here to add this to my saved trials
?
mi
from
Eugene, OR
Click here to add this to my saved trials
Florence, Alabama 35630
?
mi
from
Florence, AL
Click here to add this to my saved trials
Fort Worth, Texas 76104
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Galesburg, Illinois 61401
?
mi
from
Galesburg, IL
Click here to add this to my saved trials
Germantown, Tennessee 38138
?
mi
from
Germantown, TN
Click here to add this to my saved trials
Honolulu, Hawaii 96813
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Hudson, New York 12534
?
mi
from
Hudson, NY
Click here to add this to my saved trials
Knoxville, Tennessee 37920
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
La Jolla, California 92093
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Lewisville, Texas 75067
?
mi
from
Lewisville, TX
Click here to add this to my saved trials
Los Angeles, California 90057
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Miami Gardens, Florida 33169
?
mi
from
Miami Gardens, FL
Click here to add this to my saved trials
Middletown, Ohio 45042
?
mi
from
Middletown, OH
Click here to add this to my saved trials
?
mi
from
Nancy,
Click here to add this to my saved trials
New Orleans, Louisiana 70121
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
Newport News, Virginia 23606
?
mi
from
Newport News, VA
Click here to add this to my saved trials
Niles, Illinois 60714
?
mi
from
Niles, IL
Click here to add this to my saved trials
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Orlando, Florida 32806
?
mi
from
Orlando, FL
Click here to add this to my saved trials
?
mi
from
Roanoke, VA
Click here to add this to my saved trials
Round Rock, Texas 78665
?
mi
from
Round Rock, TX
Click here to add this to my saved trials
100 NE Loop 410; Suite 600
San Antonio, Texas 78216
210-424-1600
Cancer Care Centers of South Texas At Cancer Care Centers of South Texas, we are...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Sherman, Texas 75090
?
mi
from
Sherman, TX
Click here to add this to my saved trials
Spartanburg, South Carolina 29307
?
mi
from
Spartanburg, SC
Click here to add this to my saved trials
?
mi
from
Toledo, OH
Click here to add this to my saved trials
Tyler, Texas 75702
?
mi
from
Tyler, TX
Click here to add this to my saved trials